U2TH34 Stock Overview
A biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for U2TH34 from our risk checks.
My Notes
Capture your thoughts, links and company narrative
United Therapeutics Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$112.20 |
| 52 Week High | US$121.08 |
| 52 Week Low | US$54.20 |
| Beta | 0.55 |
| 1 Month Change | 3.89% |
| 3 Month Change | 13.68% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 94.72% |
Recent News & Updates
Recent updates
Shareholder Returns
| U2TH34 | BR Biotechs | BR Market | |
|---|---|---|---|
| 7D | 0% | -2.4% | -0.8% |
| 1Y | n/a | -2.0% | -13.7% |
Return vs Industry: Insufficient data to determine how U2TH34 performed against the BR Biotechs industry.
Return vs Market: Insufficient data to determine how U2TH34 performed against the BR Market.
Price Volatility
| U2TH34 volatility | |
|---|---|
| U2TH34 Average Weekly Movement | 5.6% |
| Biotechs Industry Average Movement | 9.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in BR Market | 9.6% |
| 10% least volatile stocks in BR Market | 2.9% |
Stable Share Price: U2TH34 has not had significant price volatility in the past 3 months compared to the BR market.
Volatility Over Time: Insufficient data to determine U2TH34's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 1,168 | Martine Rothblatt | www.unither.com |
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin.
United Therapeutics Corporation Fundamentals Summary
| U2TH34 fundamental statistics | |
|---|---|
| Market cap | R$100.78b |
| Earnings (TTM) | R$6.95b |
| Revenue (TTM) | R$17.24b |
14.5x
P/E Ratio5.8x
P/S RatioIs U2TH34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| U2TH34 income statement (TTM) | |
|---|---|
| Revenue | US$2.76b |
| Cost of Revenue | US$304.80m |
| Gross Profit | US$2.45b |
| Other Expenses | US$1.34b |
| Earnings | US$1.11b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 24.88 |
| Gross Margin | 88.94% |
| Net Profit Margin | 40.31% |
| Debt/Equity Ratio | 6.6% |
How did U2TH34 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 20:49 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
United Therapeutics Corporation is covered by 37 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| James Birchenough | Barclays |
| Derek Taller | Benchmark Company |